The HEMOLUNG and extracorporeal membrane oxygenation (ECMO) both provide temporary respiratory support while the cause of respiratory failure is addressed. ECMO is a rescue therapy intended for patients in refractory hypoxic respiratory failure. The HEMOLUNG is not intended to support patient oxygenation requirements.

The HEMOLUNG is indicated for respiratory support that provides extracorporeal carbon dioxide (CO₂) removal from the patient’s blood for up to 5 days in adults with acute, reversible respiratory failure for whom ventilation of CO₂ cannot be adequately or safely achieved using other available treatment options and continued clinical deterioration is expected.

The simplicity and minimally invasive nature of the HEMOLUNG allows it to be used much earlier compared to ECMO, even before intubation, and at non-ECMO centers.

---

Benefits of Using a Device Optimized for ECCO₂R

“There is a clear and urgent need to design dedicated blood pumps for ECCO₂R…which are optimized for blood flow rates in the range of 0.5–1.5 L/min.”¹

Operating blood pumps at the relatively low blood flow rates used in ECCO₂R is not trivial. A growing body of evidence has demonstrated increased blood damage and platelet aggregation when blood pumps designed for ECMO (>2 L/min blood flow) are operated at low blood flow rates (0.5 – 2 L/min).^1-3 These results challenge the safety of operating ECMO devices at lower blood flow rates to provide ECCO₂R.

HEMOLUNG is specifically designed for clinically relevant CO₂ removal at 350 – 550 mL/min extracorporeal blood flow rate. In addition, the safety and efficacy profile of the HEMOLUNG at these conditions are well-documented.

ADDITIONAL INFORMATION

HEMOLUNG Brochure
The HEMOLUNG System
Benefits of HEMOLUNG Therapy
HEMOLUNG Publications
Ordering Information

1. Groß-Hardt S, Hesselmann F, Arens J, et al. Low-flow assessment of current ECMO/ECCO2R rotary blood pumps and the potential effect on hemocompatibility. Crit Care. 2019;23(1):348.
2. Schöps M, Groß-Hardt SH, Schmitz-Rode T, et al. Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump. J Transl Med. 2021;19(1):2.
3. Ki KK, Passmore MR, Chan CHH, et al. Low flow rate alters haemostatic parameters in an ex-vivo extracorporeal membrane oxygenation circuit. ICMx. 2019;7(1):51.